Agreements for ARV medicines with the MPP.

Effectiveness of GeneXpert scenario compared to 100% centralized scenario over 5 years in the non-pregnant adult population.

Impact timelines by paediatric ARV treatment.

Univariate analysis for factors related to depressive symptoms among children aged 7–17 years in Southern Highlands Zone, Tanzania (X2 n = 900).

Daily cost of 2nd line ARVs for adults and pregnant women.

shRNAs used in this study.

Dialect intensity across the speech samples. Fig A shows the results of a formal linguistic test comparing the dialect intensity (i.e. regional accent in the given case) of our...

Annual average incremental costs (2016 USD) for patients retained in carea.

Prevalence of primary caregiver knowledge and practice of HIV disclosure (N = 429).

Characteristics of MSM and TW with newly diagnosed vs. previously diagnosed HIV infections who were screened for participation in HPTN 075 (N = 183).

Factors associated with non-disclosure of HIV status in bivariate and multivariate analysis (N = 429).

Innovations for scaling up care and keeping people on treatment.

Total direct savings and costs by time period (USD).

Cost per day for ARV medications a.

Description of women is study sample (n = 1548).

Results of key secondary endpoints from identified trials among ARV-naive patients.

BackgroundDespite compelling evidence for activity against HIV-1 in vitro, a virologic effect of statins has not been shown in clinical studies. Given their short plasma...

Effectiveness of GeneXpert scenario compared to 100% centralized scenario over 31 months in the pregnant population.

We used Latin-hypercube sampling to generate 1,000 combinations of the following parameters: basic reproductive number R0, linear scale on interval (1,3); generation time TG,...

Study designs for identified trials in ARV-naive patients.